---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-007007"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:14:22.281686+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acrivon reports positive ACR-368 Phase 2b data in serous EC; ACR-2316 shows tumor shrinkage in Phase 1

## Summary
- ACR-368 Phase 2b: 39% ORR overall; in serous EC ≤2 prior lines, cORR 52% (N=23) and 67% in BM+ (N=12). Arm 3 expanding to EU, enrollment complete Q4 2026.
- ACR-2316 Phase 1: 33 patients dosed; tumor shrinkage in 9/20 evaluable; confirmed PR in EC, unconfirmed PRs in SCLC and sqNSCLC. Two weekly schedules set.
- ACR-6840, a potential first-in-class CDK11 inhibitor, nominated as development candidate; IND submission planned for Q4 2026.
- Preliminary cash, cash equivalents and investments ~$119M as of Dec 31, 2025, expected to fund operations into Q2 2027.
- Phase 3 confirmatory protocol for ACR-368 + anti-PD-1 submitted to FDA Nov 2025; global trial readiness expected mid-2026.

## SEC filing metadata
- accession: 0001193125-26-007007
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312526007007/0001193125-26-007007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312526007007/acrv-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-007007
- JSON: https://secwatch.observer/filing/0001193125-26-007007.json
- Plain text: https://secwatch.observer/filing/0001193125-26-007007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.